Medical Research

American Heart Association Launches Major Initiative to Address Treatment Gaps in Common Heart Failure Types

American Heart Association Launches Major Initiative to Address Treatment Gaps in Common Heart Failure Types

The American Heart Association's new three-year IMPLEMENT-EF initiative aims to improve care for the 75% of heart failure patients with preserved or mildly reduced ejection fraction, addressing significant evidence gaps through multidisciplinary team approaches and real-world data analysis.

September 15, 2025
UCLA Researcher Peter Tontonoz to Receive 2025 American Heart Association Basic Research Prize for Lipid Metabolism Discoveries

UCLA Researcher Peter Tontonoz to Receive 2025 American Heart Association Basic Research Prize for Lipid Metabolism Discoveries

Dr. Peter Tontonoz's groundbreaking research on cholesterol and lipid metabolism has transformed understanding of cardiovascular diseases and paved the way for new treatments beyond statins.

September 15, 2025
Hot and Cold Therapy Gains Scientific Backing for Heart Health and Immune Benefits

Hot and Cold Therapy Gains Scientific Backing for Heart Health and Immune Benefits

Medical expert Dr. Roger Seheult explains how combining sauna use with cold plunging provides significant cardiovascular and immune system benefits through ancient practices now supported by modern science.

September 13, 2025
Study Links Sucralose Consumption to Reduced Effectiveness of Cancer Immunotherapy

Study Links Sucralose Consumption to Reduced Effectiveness of Cancer Immunotherapy

University of Pittsburgh research reveals that regular consumption of the artificial sweetener sucralose may diminish the effectiveness of immunotherapy treatments and reduce survival times in cancer patients.

September 12, 2025
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients

GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients

GeoVax Labs' GEO-CM04S1 vaccine demonstrates robust immunity in high-risk patients with blood cancers, potentially addressing a multi-billion dollar market where current vaccines have limited effectiveness.

September 12, 2025
Neuroscience Breakthrough Offers New Hope for Locked-In Syndrome Patients and Consciousness Research

Neuroscience Breakthrough Offers New Hope for Locked-In Syndrome Patients and Consciousness Research

Dr. Berenika Maciejewicz's research provides a new diagnostic framework for detecting consciousness in locked-in syndrome patients, with significant implications for brain-computer interfaces and neurological care.

September 12, 2025
Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results

Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results

Kairos Pharma will present interim efficacy results from its Phase 2 trial of ENV105 in advanced prostate cancer, potentially addressing critical drug resistance challenges in oncology treatment.

September 11, 2025
Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Dialysis-Like Cardiovascular Therapy

Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Dialysis-Like Cardiovascular Therapy

Sigyn Therapeutics has appointed Dr. Christoph Zaba, an expert in extracorporeal therapies, to its Scientific Advisory Board to support the development of Sigyn Therapy™, a novel treatment designed to reduce cardiovascular disease risk factors using existing dialysis infrastructure.

September 11, 2025
NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025

NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025

NanoViricides will showcase its clinical-stage nanoviricide technology targeting multiple viral diseases at the LSX World Congress, highlighting its potential to address unmet medical needs through a novel antiviral approach.

September 10, 2025
Soligenix Expands Rare Disease and Public Health Pipeline in Latest Corporate Strategy Update

Soligenix Expands Rare Disease and Public Health Pipeline in Latest Corporate Strategy Update

Soligenix Inc. showcases its dual-focused strategy addressing both rare diseases with unmet medical needs and critical public health threats through its latest corporate presentation, positioning the company as a significant player in specialized therapeutics and biodefense solutions.

September 9, 2025
Gyre Therapeutics Advances Hydronidone Toward China Approval and Expands Clinical Pipeline

Gyre Therapeutics Advances Hydronidone Toward China Approval and Expands Clinical Pipeline

Gyre Therapeutics has submitted Hydronidone for approval in China and initiated a U.S. Phase 2 trial, positioning the company for significant growth in liver fibrosis treatment markets.

September 9, 2025
WHAM Edge Awards 2025 to Fund Early-Career Researchers in Women's Health

WHAM Edge Awards 2025 to Fund Early-Career Researchers in Women's Health

The WHAM Edge Awards provide critical $25,000 grants to early-career researchers investigating how biological sex influences health outcomes, addressing systemic funding gaps and economic disparities in women's health research.

September 9, 2025
Study Reveals Only 14% of Online Blood Pressure Images Show Correct Measurement Technique

Study Reveals Only 14% of Online Blood Pressure Images Show Correct Measurement Technique

New research finds that just 1 in 7 online stock images accurately depict proper blood pressure measurement techniques, potentially leading to widespread incorrect readings and treatment decisions.

September 8, 2025
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients

GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients

GeoVax Labs will present clinical data demonstrating that its GEO-CM04S1 vaccine generates cross-variant antibody and robust cellular immune responses in immunocompromised patients with hematologic malignancies, potentially addressing a critical gap in COVID-19 protection for vulnerable populations.

September 8, 2025
National Survey Reveals Nearly Half of US Adults Experience Unexplained or Treatment-Resistant Pain and Illness

National Survey Reveals Nearly Half of US Adults Experience Unexplained or Treatment-Resistant Pain and Illness

A groundbreaking national survey to be presented at the Association for the Treatment of Neuroplastic Symptoms conference shows that 40% of Americans seeking medical care have symptoms likely caused by stress-induced neural pathway changes rather than structural issues.

September 8, 2025
Childhood High Blood Pressure Linked to 40-50% Higher Risk of Early Cardiovascular Death

Childhood High Blood Pressure Linked to 40-50% Higher Risk of Early Cardiovascular Death

New research reveals that children with elevated blood pressure at age 7 face significantly increased risk of premature cardiovascular death by mid-50s, highlighting the critical importance of early blood pressure monitoring and heart-healthy habits.

September 7, 2025
New Medication Baxdrostat Shows Promise in Lowering Blood Pressure and Slowing Kidney Disease Progression

New Medication Baxdrostat Shows Promise in Lowering Blood Pressure and Slowing Kidney Disease Progression

The novel medication baxdrostat demonstrated significant reductions in systolic blood pressure and urine albumin levels in patients with chronic kidney disease and uncontrolled hypertension, potentially offering new treatment options for this high-risk population.

September 6, 2025
NCI Ends 26-Year Funding for Pediatric Brain Cancer Research Consortium

NCI Ends 26-Year Funding for Pediatric Brain Cancer Research Consortium

The National Cancer Institute's termination of funding for a long-running pediatric brain cancer research program highlights growing reliance on private sector entities like CNS Pharmaceuticals Inc. to advance critical childhood cancer treatments.

September 5, 2025
Chiropractic Study Shows Non-Surgical Recovery From Severe Disc Injuries

Chiropractic Study Shows Non-Surgical Recovery From Severe Disc Injuries

A new study published in the Journal of Contemporary Chiropractic demonstrates that non-surgical chiropractic care can effectively manage massive lumbar disc herniations, offering a conservative alternative to invasive surgical treatments.

September 3, 2025
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference

Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference

Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.

September 3, 2025
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease

InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease

InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.

September 3, 2025
New Research Reveals 62% of AFib Patients Unaware of Condition Before Diagnosis

New Research Reveals 62% of AFib Patients Unaware of Condition Before Diagnosis

A new American Heart Association study shows most atrial fibrillation patients were unaware of their condition before diagnosis, highlighting critical gaps in public awareness about this serious heart rhythm disorder that significantly increases stroke risk.

September 3, 2025
Study Links Self-Medicating with Cannabis to Increased Paranoia Risk

Study Links Self-Medicating with Cannabis to Increased Paranoia Risk

New research indicates that individuals using marijuana to cope with depression, anxiety, or pain face higher paranoia risks compared to recreational users, while licensed operators may help reduce associated stigma.

September 2, 2025
Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research

Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research

A Mass General Brigham study of 75,000 patients reveals traumatic brain injuries elevate malignant brain tumor risk, highlighting the importance of ongoing treatment development by companies like CNS Pharmaceuticals Inc.

September 2, 2025
Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner

Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner

Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism, including a Best Poster award-winning presentation detailing its mechanism of action for treating Niemann-Pick disease type C, highlighting significant advancements in rare disease treatment.

August 29, 2025
New PREVENT Equations Transform Cardiovascular Risk Assessment and Personalize Hypertension Treatment

New PREVENT Equations Transform Cardiovascular Risk Assessment and Personalize Hypertension Treatment

The American Heart Association's PREVENT equations provide more accurate cardiovascular disease risk predictions, enabling personalized treatment decisions for adults with high blood pressure while addressing concerns about overtreatment.

August 28, 2025
University of Utah Study Identifies Mechanism Behind Blood Clot Risk in IBD Patients

University of Utah Study Identifies Mechanism Behind Blood Clot Risk in IBD Patients

New research from the University of Utah reveals why inflammatory bowel disease patients face elevated blood clot risks and suggests potential dual-treatment approaches that could address both clotting and inflammation.

August 28, 2025
MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research

MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research

MyBioSource has introduced a validated sheep anti-rat calretinin polyclonal antibody that enables advanced research into calcium signaling, neuroprotection, and neurodegeneration across multiple species.

August 28, 2025
Soligenix Advances Rare Disease Pipeline with Key Clinical Milestones Expected Through 2026

Soligenix Advances Rare Disease Pipeline with Key Clinical Milestones Expected Through 2026

Soligenix Inc. reports significant progress in its late-stage rare disease treatments, including pivotal Phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies that could transform care for underserved patient populations.

August 26, 2025
World Heart Federation Honors American Heart Association CEO with Lifetime Achievement Award

World Heart Federation Honors American Heart Association CEO with Lifetime Achievement Award

Nancy Brown receives global recognition for her transformative leadership in advancing cardiovascular health worldwide through scientific innovation and quality improvement initiatives.

August 26, 2025
PreviousPage 5 of 11Next